Beta-catenin signaling, liver regeneration and hepatocellular cancer: Sorting the good from the bad

Seminars in Cancer Biology

Volumn 21, Issue 1, 2011, Pages 44-58

  Nejak Bowen, Kari Nichole ^a   Monga, Satdarshan P S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrosis; HCC; Injury; Liver regeneration; Oval cells; Wnt beta catenin

Indexed keywords

BETA CATENIN; WNT PROTEIN;

CANCER STEM CELL; CELL ACTIVATION; CELL ADHESION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL JUNCTION; CELL PROLIFERATION; CHROMOSOME ABERRATION; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HUMAN; INTRACELLULAR SIGNALING; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DEVELOPMENT; LIVER FUNCTION; LIVER REGENERATION; NONHUMAN; POSTNATAL GROWTH; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LIVER REGENERATION; SIGNAL TRANSDUCTION; STEM CELLS; WNT PROTEINS;

EID: 79952043062     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.12.010     Document Type: Review

References (199)

1. Wodarz A., Nusse R. Mechanisms of Wnt signaling in development. Ann Rev Cell Dev Biol 1998, 14:59-88.
2. Cadigan K.M., Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997, 11:3286-3305.
3. Nusse R. Wnt signaling in disease and in development. Cell Res 2005, 15:28-32.
4. Logan C.Y., Nusse R. The Wnt signaling pathway in development and disease. Ann Rev Cell Dev Biol 2004, 20:781-810.
5. Peifer M., Polakis P. Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science (New York, NY) 2000, 287:1606-1609.
6. Willert K., Brown J.D., Danenberg E., Duncan A.W., Weissman I.L., Reya T., et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003, 423:448-452.
7. Thompson M.D., Monga S.P. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007, 45:1298-1305.
8. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
9. Wong H.C., Bourdelas A., Krauss A., Lee H.J., Shao Y., Wu D., et al. Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. Mol Cell 2003, 12:1251-1260.
10. Cliffe A., Hamada F., Bienz M. A role of Dishevelled in relocating Axin to the plasma membrane during wingless signaling. Curr Biol 2003, 13:960-966.
11. Zeng X., Huang H., Tamai K., Zhang X., Harada Y., Yokota C., et al. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development (Cambridge, England) 2008, 135:367-375.
12. Zeng X., Tamai K., Doble B., Li S., Huang H., Habas R., et al. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 2005, 438:873-877.
13. Cadigan K.M., Liu Y.I. Wnt signaling: complexity at the surface. J Cell Sci 2006, 119:395-402.
14. Yokoya F., Imamoto N., Tachibana T., Yoneda Y. beta-catenin can be transported into the nucleus in a Ran-unassisted manner. Mol Biol Cell 1999, 10:1119-1131.
15. Huber O., Korn R., McLaughlin J., Ohsugi M., Herrmann B.G., Kemler R. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev 1996, 59:3-10.
16. Zeng G., Awan F., Otruba W., Muller P., Apte U., Tan X., et al. Wnt'er in liver: expression of Wnt and frizzled genes in mouse. Hepatology 2007, 45:195-204.
17. Decaens T., Godard C., de Reynies A., Rickman D.S., Tronche F., Couty J.P., et al. Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate. Hepatology 2008, 47:247-258.
18. Hussain S.Z., Sneddon T., Tan X., Micsenyi A., Michalopoulos G.K., Monga S.P. Wnt impacts growth and differentiation in ex vivo liver development. Exp Cell Res 2004, 292:157-169.
19. Monga S.P., Monga H.K., Tan X., Mule K., Pediaditakis P., Michalopoulos G.K. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 2003, 124:202-216.
20. Thompson M.D., Awuah P., Singh S., Monga S.P. Disparate cellular basis of improved liver repair in beta-catenin-overexpressing mice after long-term exposure to 3,5-diethoxycarbonyl-1,4-dihydrocollidine. Am J Pathol 2010, 177:1812-1822.
21. Klein D., Demory A., Peyre F., Kroll J., Augustin H.G., Helfrich W., et al. Wnt2 acts as a cell type-specific, autocrine growth factor in rat hepatic sinusoidal endothelial cells cross-stimulating the VEGF pathway. Hepatology 2008, 47:1018-1031.
22. Kordes C., Sawitza I., Haussinger D. Canonical Wnt signaling maintains the quiescent stage of hepatic stellate cells. Biochem Biophys Res Commun 2008, 367:116-123.
23. Cheng J.H., She H., Han Y.P., Wang J., Xiong S., Asahina K., et al. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008, 294:G39-G49.
24. Jiang F., Parsons C.J., Stefanovic B. Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J Hepatol 2006, 45:401-409.
25. Benhamouche S., Decaens T., Godard C., Chambrey R., Rickman D.S., Moinard C., et al. Apc tumor suppressor gene is the " zonation-keeper" of mouse liver. Dev Cell 2006, 10:759-770.
26. Braeuning A., Menzel M., Kleinschnitz E.M., Harada N., Tamai Y., Kohle C., et al. Serum components and activated Ha-ras antagonize expression of perivenous marker genes stimulated by beta-catenin signaling in mouse hepatocytes. FEBS J 2007, 274:4766-4777.
27. Colletti M., Cicchini C., Conigliaro A., Santangelo L., Alonzi T., Pasquini E., et al. Convergence of Wnt signaling on the HNF4alpha-driven transcription in controlling liver zonation. Gastroenterology 2009, 137:660-672.
28. Lilien J., Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin. Curr Opin Cell Biol 2005, 17:459-465.
29. Orsulic S., Huber O., Aberle H., Arnold S., Kemler R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci 1999, 112(Pt 8):1237-1245.
30. Aberle H., Butz S., Stappert J., Weissig H., Kemler R., Hoschuetzky H. Assembly of the cadherin-catenin complex in vitro with recombinant proteins. J Cell Sci 1994, 107(Pt 12):3655-3663.
31. Piedra J., Martinez D., Castano J., Miravet S., Dunach M., de Herreros A.G. Regulation of beta-catenin structure and activity by tyrosine phosphorylation. J Biol Chem 2001, 276:20436-20443.
32. Roura S., Miravet S., Piedra J., Garcia de Herreros A., Dunach M. Regulation of E-cadherin/Catenin association by tyrosine phosphorylation. J Biol Chem 1999, 274:36734-36740.
33. Theard D., Steiner M., Kalicharan D., Hoekstra D., van Ijzendoorn S.C. Cell polarity development and protein trafficking in hepatocytes lacking E-cadherin/beta-catenin-based adherens junctions. Mol Biol Cell 2007, 18:2313-2321.
34. Gumbiner B.M. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev 2005, 6:622-634.
35. Zarnegar R. Regulation of HGF and HGFR gene expression. EXS 1995, 74:33-49.
36. Monga S.P., Mars W.M., Pediaditakis P., Bell A., Mule K., Bowen W.C., et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002, 62:2064-2071.
37. Papkoff J., Aikawa M. WNT-1 and HGF regulate GSK3 beta activity and beta-catenin signaling in mammary epithelial cells. Biochem Biophys Res Commun 1998, 247:851-858.
38. Zeng G., Apte U., Micsenyi A., Bell A., Monga S.P. Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation of Met-beta-catenin interactions. Exp Cell Res 2006, 312:3620-3630.
39. Ishibe S., Haydu J.E., Togawa A., Marlier A., Cantley L.G. Cell confluence regulates hepatocyte growth factor-stimulated cell morphogenesis in a beta-catenin-dependent manner. Mol Cell Biol 2006, 26:9232-9243.
40. Monga S.P., Micsenyi A., Germinaro M., Apte U., Bell A. beta-Catenin regulation during matrigel-induced rat hepatocyte differentiation. Cell Tissue Res 2006, 323:71-79.
41. Shibamoto S., Hayakawa M., Takeuchi K., Hori T., Oku N., Miyazawa K., et al. Tyrosine phosphorylation of beta-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells. Cell Adhes Commun 1994, 1:295-305.
42. Apte U., Zeng G., Muller P., Tan X., Micsenyi A., Cieply B., et al. Activation of Wnt/beta-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice. Hepatology 2006, 44:992-1002.
43. Patil M.A., Lee S.A., Macias E., Lam E.T., Xu C., Jones K.D., et al. Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. Cancer Res 2009, 69:253-261.
44. Tward A.D., Jones K.D., Yant S., Cheung S.T., Fan S.T., Chen X., et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci USA 2007, 104:14771-14776.
45. Shibata T., Ochiai A., Kanai Y., Akimoto S., Gotoh M., Yasui N., et al. Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. Oncogene 1996, 13:883-889.
46. Bonvini P., An W.G., Rosolen A., Nguyen P., Trepel J., Garcia de Herreros A., et al. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. Cancer Res 2001, 61:1671-1677.
47. Wang K., Ma Q., Ren Y., He J., Zhang Y., Zhang Y., et al. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells. Oncol Rep 2007, 17:89-96.
48. Tan X., Apte U., Micsenyi A., Kotsagrelos E., Luo J.H., Ranganathan S., et al. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology 2005, 129:285-302.
49. Boon E.M., van der Neut R., van de Wetering M., Clevers H., Pals S.T. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 2002, 62:5126-5128.
50. Rodilla V., Villanueva A., Obrador-Hevia A., Robert-Moreno A., Fernandez-Majada V., Grilli A., et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci USA 2009, 106:6315-6320.
51. Koh T.J., Bulitta C.J., Fleming J.V., Dockray G.J., Varro A., Wang T.C. Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest 2000, 106:533-539.
52. Brabletz T., Jung A., Dag S., Hlubek F., Kirchner T. beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999, 155:1033-1038.
53. Zhang T., Otevrel T., Gao Z., Gao Z., Ehrlich S.M., Fields J.Z., et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001, 61:8664-8667.
54. Hendrix N.D., Wu R., Kuick R., Schwartz D.R., Fearon E.R., Cho K.R. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 2006, 66:1354-1362.
55. Chamorro M.N., Schwartz D.R., Vonica A., Brivanlou A.H., Cho K.R., Varmus H.E. FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J 2005, 24:73-84.
56. Shimokawa T., Furukawa Y., Sakai M., Li M., Miwa N., Lin Y.M., et al. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex. Cancer Res 2003, 63:6116-6120.
57. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999, 96:5522-5527.
58. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426.
59. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., et al. Identification of c-MYC as a target of the APC pathway. Science (New York, NY) 1998, 281:1509-1512.
60. Cadoret A., Ovejero C., Terris B., Souil E., Levy L., Lamers W.H., et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 2002, 21:8293-8301.
61. Giera S., Braeuning A., Kohle C., Bursch W., Metzger U., Buchmann A., et al. Wnt/beta-catenin signaling activates and determines hepatic zonal expression of glutathione S-transferases in mouse liver. Toxicol Sci 2010, 115:22-33.
62. Loeppen S., Koehle C., Buchmann A., Schwarz M. A beta-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. Carcinogenesis 2005, 26:239-248.
63. Nejak-Bowen K., Monga S.P. Wnt/beta-catenin signaling in hepatic organogenesis. Organogenesis 2008, 4:92-99.
64. Ovejero C., Cavard C., Perianin A., Hakvoort T., Vermeulen J., Godard C., et al. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver. Hepatology 2004, 40:167-176.
65. Sekine S., Lan B.Y., Bedolli M., Feng S., Hebrok M. Liver-specific loss of beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice. Hepatology 2006, 43:817-825.
66. Tan X., Behari J., Cieply B., Michalopoulos G.K., Monga S.P. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 2006, 131:1561-1572.
67. Leung J.Y., Kolligs F.T., Wu R., Zhai Y., Kuick R., Hanash S., et al. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem 2002, 277:21657-21665.
68. Roose J., Huls G., van Beest M., Moerer P., van der Horn K., Goldschmeding R., et al. Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. Science (New York, NY) 1999, 285:1923-1926.
69. Cadigan K.M., Fish M.P., Rulifson E.J., Nusse R. Wingless repression of Drosophila frizzled 2 expression shapes the Wingless morphogen gradient in the wing. Cell 1998, 93:767-777.
70. Khan Z., Vijayakumar S., de la Torre T.V., Rotolo S., Bafico A. Analysis of endogenous LRP6 function reveals a novel feedback mechanism by which Wnt negatively regulates its receptor. Mol Cell Biol 2007, 27:7291-7301.
71. Austinat M., Dunsch R., Wittekind C., Tannapfel A., Gebhardt R., Gaunitz F. Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer 2008, 7:21.
72. Cieply B., Zeng G., Proverbs-Singh T., Geller D.A., Monga S.P. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009, 49:821-831.
73. Hoshida Y., Nijman S.M., Kobayashi M., Chan J.A., Brunet J.P., Chiang D.Y., et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009, 69:7385-7392.
74. Hsu H.C., Jeng Y.M., Mao T.L., Chu J.S., Lai P.L., Peng S.Y. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000, 157:763-770.
75. Zucman-Rossi J., Benhamouche S., Godard C., Boyault S., Grimber G., Balabaud C., et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007, 26:774-780.
76. Hovanes K., Li T.W., Munguia J.E., Truong T., Milovanovic T., Lawrence Marsh J., et al. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 2001, 28:53-57.
77. MacDonald B.T., Tamai K., He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009, 17:9-26.
78. Michalopoulos G.K., DeFrances M.C. Liver regeneration. Science (New York, NY) 1997, 276:60-66.
79. Higgins G.M., Anderson R.M. Experimental pathology of the liver, 1: restoration of the liver of the white rat following partial surgical removal. Arch Pathol 1931, 12:186-202.
80. Michalopoulos G.K. Liver regeneration. J Cell Physiol 2007, 213:286-300.
81. Taub R. Liver regeneration 4: transcriptional control of liver regeneration. FASEB J 1996, 10:413-427.
82. Su A.I., Guidotti L.G., Pezacki J.P., Chisari F.V., Schultz P.G. Gene expression during the priming phase of liver regeneration after partial hepatectomy in mice. Proc Natl Acad Sci USA 2002, 99:11181-11186.
83. White P., Brestelli J.E., Kaestner K.H., Greenbaum L.E. Identification of transcriptional networks during liver regeneration. J Biol Chem 2005, 280:3715-3722.
84. Walker P.R., Potter V.R. Isozyme studies on adult, regenerating, precancerous and developing liver in relation to findings in hepatomas. Adv Enzyme Regul 1972, 10:339-364.
85. Rabes H.M. Kinetics of hepatocellular proliferation as a function of the microvascular structure and functional state of the liver. Ciba Found Symp 1977, 31-53.
86. Stocker E., Heine W.D. Regeneration of liver parenchyma under normal and pathological conditions. Beitr Pathol 1971, 144:400-408.
87. Stocker E., Wullstein H.K., Brau G. Capacity of regeneration in liver epithelia of juvenile, repeated partially hepatectomized rats. Autoradiographic studies after continuous infusion of 3H-thymidine (author's transl). Virchows Arch B Cell Pathol 1973, 14:93-103.
88. Grisham J.W. A morphologic study of deoxyribonucleic acid synthesis and cell proliferation in regenerating rat liver; autoradiography with thymidine-H3. Cancer Res 1962, 22:842-849.
89. Nelsen C.J., Rickheim D.G., Timchenko N.A., Stanley M.W., Albrecht J.H. Transient expression of cyclin D1 is sufficient to promote hepatocyte replication and liver growth in vivo. Cancer Res 2001, 61:8564-8568.
90. Apte U., Zeng G., Thompson M.D., Muller P., Micsenyi A., Cieply B., et al. beta-Catenin is critical for early postnatal liver growth. Am J Physiol Gastrointest Liver Physiol 2007, 292:G1578-G1585.
91. Cadoret A., Ovejero C., Saadi-Kheddouci S., Souil E., Fabre M., Romagnolo B., et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res 2001, 61:3245-3249.
92. Harada N., Miyoshi H., Murai N., Oshima H., Tamai Y., Oshima M., et al. Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res 2002, 62:1971-1977.
93. Monga S.P., Pediaditakis P., Mule K., Stolz D.B., Michalopoulos G.K. Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration. Hepatology 2001, 33:1098-1109.
94. Pediaditakis P., Lopez-Talavera J.C., Petersen B., Monga S.P., Michalopoulos G.K. The processing and utilization of hepatocyte growth factor/scatter factor following partial hepatectomy in the rat. Hepatology 2001, 34:688-693.
95. Haegel H., Larue L., Ohsugi M., Fedorov L., Herrenknecht K., Kemler R. Lack of beta-catenin affects mouse development at gastrulation. Development (Cambridge, England) 1995, 121:3529-3537.
96. Grigoryan T., Wend P., Klaus A., Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev 2008, 22:2308-2341.
97. Sodhi D., Micsenyi A., Bowen W.C., Monga D.K., Talavera J.C., Monga S.P. Morpholino oligonucleotide-triggered beta-catenin knockdown compromises normal liver regeneration. J Hepatol 2005, 43:132-141.
98. Sekine S., Gutierrez P.J., Lan B.Y., Feng S., Hebrok M. Liver-specific loss of beta-catenin results in delayed hepatocyte proliferation after partial hepatectomy. Hepatology 2007, 45:361-368.
99. Apte U., Singh S., Zeng G., Cieply B., Virji M.A., Wu T., et al. Beta-catenin activation promotes liver regeneration after acetaminophen-induced injury. Am J Pathol 2009, 175:1056-1065.
100. Colnot S., Decaens T., Niwa-Kawakita M., Godard C., Hamard G., Kahn A., et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci USA 2004, 101:17216-17221.
101. Goessling W., North T.E., Lord A.M., Ceol C., Lee S., Weidinger G., et al. APC mutant zebrafish uncover a changing temporal requirement for Wnt signaling in liver development. Dev Biol 2008, 320:161-174.
102. Qian J., Sarnaik A.A., Bonney T.M., Keirsey J., Combs K.A., Steigerwald K., et al. The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus. Gastroenterology 2008, 135:152-162.
103. Prosperi J.R., Becher K.R., Willson T.A., Collins M.H., Witte D.P., Goss K.H. The APC tumor suppressor is required for epithelial integrity in the mouse mammary gland. J Cell Physiol 2009, 220:319-331.
104. Nejak-Bowen K.N., Thompson M.D., Singh S., Bowen W.C., Dar M.J., Khillan J., et al. Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. Hepatology 2010, 51:1603-1613.
105. Manisastry S.M., Han M., Linask K.K. Early temporal-specific responses and differential sensitivity to lithium and Wnt-3A exposure during heart development. Dev Dyn 2006, 235:2160-2174.
106. Matthews V.B., Yeoh G.C. Liver stem cells. IUBMB Life 2005, 57:549-553.
107. Oertel M., Shafritz D.A. Stem cells, cell transplantation and liver repopulation. Biochim Biophys Acta 2008, 1782:61-74.
108. Oh S.H., Hatch H.M., Petersen B.E. Hepatic oval 'stem' cell in liver regeneration. Semin Cell Dev Biol 2002, 13:405-409.
109. Farber E. Similarities in the sequence of early histological changes induced in the liver of the rat by ethionine, 2-acetylamino-fluorene, and 3′-methyl-4-dimethylaminoazobenzene. Cancer Res 1956, 16:142-148.
110. Kuwahara R., Kofman A.V., Landis C.S., Swenson E.S., Barendswaard E., Theise N.D. The hepatic stem cell niche: identification by label-retaining cell assay. Hepatology 2008, 47:1994-2002.
111. Sell S. Comparison of liver progenitor cells in human atypical ductular reactions with those seen in experimental models of liver injury. Hepatology 1998, 27:317-331.
112. Yovchev M.I., Grozdanov P.N., Zhou H., Racherla H., Guha C., Dabeva M.D. Identification of adult hepatic progenitor cells capable of repopulating injured rat liver. Hepatology 2008, 47:636-647.
113. Sell S., Leffert H.L. Liver cancer stem cells. J Clin Oncol 2008, 26:2800-2805.
114. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006, 25:3818-3822.
115. de Lima V.M., Oliveira C.P., Alves V.A., Chammas M.C., Oliveira E.P., Stefano J.T., et al. A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. J Hepatol 2008, 49:1055-1061.
116. Bennoun M., Rissel M., Engelhardt N., Guillouzo A., Briand P., Weber-Benarous A. Oval cell proliferation in early stages of hepatocarcinogenesis in simian virus 40 large T transgenic mice. Am J Pathol 1993, 143:1326-1336.
117. Evarts R.P., Nagy P., Marsden E., Thorgeirsson S.S. A precursor-product relationship exists between oval cells and hepatocytes in rat liver. Carcinogenesis 1987, 8:1737-1740.
118. Paku S., Schnur J., Nagy P., Thorgeirsson S.S. Origin and structural evolution of the early proliferating oval cells in rat liver. Am J Pathol 2001, 158:1313-1323.
119. Petersen B.E., Zajac V.F., Michalopoulos G.K. Bile ductular damage induced by methylene dianiline inhibits oval cell activation. Am J Pathol 1997, 151:905-909.
120. Akhurst B., Croager E.J., Farley-Roche C.A., Ong J.K., Dumble M.L., Knight B., et al. A modified choline-deficient, ethionine-supplemented diet protocol effectively induces oval cells in mouse liver. Hepatology 2001, 34:519-522.
121. Preisegger K.H., Factor V.M., Fuchsbichler A., Stumptner C., Denk H., Thorgeirsson S.S. Atypical ductular proliferation and its inhibition by transforming growth factor beta1 in the 3,5-diethoxycarbonyl-1,4-dihydrocollidine mouse model for chronic alcoholic liver disease. Lab Invest 1999, 79:103-109.
122. Jelnes P., Santoni-Rugiu E., Rasmussen M., Friis S.L., Nielsen J.H., Tygstrup N., et al. Remarkable heterogeneity displayed by oval cells in rat and mouse models of stem cell-mediated liver regeneration. Hepatology 2007, 45:1462-1470.
123. Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology 2004, 39:1477-1487.
124. Lazaro C.A., Rhim J.A., Yamada Y., Fausto N. Generation of hepatocytes from oval cell precursors in culture. Cancer Res 1998, 58:5514-5522.
125. Alison M.R., Islam S., Lim S. Stem cells in liver regeneration, fibrosis and cancer: the good, the bad and the ugly. J Pathol 2009, 217:282-298.
126. Sell S. Cellular origin of hepatocellular carcinomas. Semin Cell Dev Biol 2002, 13:419-424.
127. Ma S., Chan K.W., Hu L., Lee T.K., Wo J.Y., Ng I.O., et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132:2542-2556.
128. Suetsugu A., Nagaki M., Aoki H., Motohashi T., Kunisada T., Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006, 351:820-824.
129. Rountree C.B., Senadheera S., Mato J.M., Crooks G.M., Lu S.C. Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice. Hepatology 2008, 47:1288-1297.
130. Lee J.S., Heo J., Libbrecht L., Chu I.S., Kaposi-Novak P., Calvisi D.F., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006, 12:410-416.
131. Vander Borght S., Komuta M., Libbrecht L., Katoonizadeh A., Aerts R., Dymarkowski S., et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 2008, 28:1370-1380.
132. Yamashita T., Ji J., Budhu A., Forgues M., Yang W., Wang H.Y., et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009, 136:1012-1024.
133. Yamashita T., Budhu A., Forgues M., Wang X.W. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007, 67:10831-10839.
134. Fodde R., Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007, 19:150-158.
135. Nusse R., Fuerer C., Ching W., Harnish K., Logan C., Zeng A., et al. Wnt signaling and stem cell control. Cold Spring Harb Symp Quant Biol 2008, 73:59-66.
136. Hu M., Kurobe M., Jeong Y.J., Fuerer C., Ghole S., Nusse R., et al. Wnt/beta-catenin signaling in murine hepatic transit amplifying progenitor cells. Gastroenterology 2007, 133:1579-1591.
137. Apte U., Thompson M.D., Cui S., Liu B., Cieply B., Monga S.P. Wnt/beta-catenin signaling mediates oval cell response in rodents. Hepatology 2008, 47:288-295.
138. Zhang Y., Li X.M., Zhang F.K., Wang B.E. Activation of canonical Wnt signaling pathway promotes proliferation and self-renewal of rat hepatic oval cell line WB-F344 in vitro. World J Gastroenterol 2008, 14:6673-6680.
139. Itoh T., Kamiya Y., Okabe M., Tanaka M., Miyajima A. Inducible expression of Wnt genes during adult hepatic stem/progenitor cell response. FEBS Lett 2009, 583:777-781.
140. Williams J.M., Oh S.H., Jorgensen M., Steiger N., Darwiche H., Shupe T., et al. The role of the Wnt family of secreted proteins in rat oval " stem" cell-based liver regeneration: Wnt1 drives differentiation. Am J Pathol 2010, 176:2732-2742.
141. Spee B., Carpino G., Schotanus B.A., Katoonizadeh A., Vander Borght S., Gaudio E., et al. Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut 2010, 59:247-257.
142. Chiba T., Zheng Y.W., Kita K., Yokosuka O., Saisho H., Onodera M., et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 2007, 133:937-950.
143. Yang W., Yan H.X., Chen L., Liu Q., He Y.Q., Yu L.X., et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 2008, 68:4287-4295.
144. Kitisin K., Pishvaian M.J., Johnson L.B., Mishra L. Liver stem cells and molecular signaling pathways in hepatocellular carcinoma. Gastrointest Cancer Res 2007, 1:S13-S21.
145. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010.
146. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687.
147. Villanueva A., Newell P., Chiang D.Y., Friedman S.L., Llovet J.M. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27:55-76.
148. Wong C.M., Ng I.O. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008, 28:160-174.
149. Lok A.S., Seeff L.B., Morgan T.R., di Bisceglie A.M., Sterling R.K., Curto T.M., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136:138-148.
150. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
151. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991, 350:429-431.
152. Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991, 350:427-428.
153. de La Coste A., Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998, 95:8847-8851.
154. Yao Y.J., Ping X.L., Zhang H., Chen F.F., Lee P.K., Ahsan H., et al. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 1999, 18:3181-3185.
155. Zender L., Villanueva A., Tovar V., Sia D., Chiang D.Y., Llovet J.M. Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010, 52:921-929.
156. Finn R.S., Zhu A.X. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009, 9:503-509.
157. Harada N., Oshima H., Katoh M., Tamai Y., Oshima M., Taketo M.M. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res 2004, 64:48-54.
158. Miyoshi H., Deguchi A., Nakau M., Kojima Y., Mori A., Oshima M., et al. Hepatocellular carcinoma development induced by conditional beta-catenin activation in Lkb1+/- mice. Cancer Sci 2009, 100:2046-2053.
159. Bauer-Hofmann R., Klimek F., Buchmann A., Muller O., Bannasch P., Schwarz M. Role of mutations at codon 61 of the c-Ha-ras gene during diethylnitrosamine-induced hepatocarcinogenesis in C3H/He mice. Mol Carcinog 1992, 6:60-67.
160. Haramis A.P., Hurlstone A., van der Velden Y., Begthel H., van den Born M., Offerhaus G.J., et al. Adenomatous polyposis coli-deficient zebrafish are susceptible to digestive tract neoplasia. EMBO Rep 2006, 7:444-449.
161. Aydinlik H., Nguyen T.D., Moennikes O., Buchmann A., Schwarz M. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene 2001, 20:7812-7816.
162. Schwarz M., Wanke I., Wulbrand U., Moennikes O., Buchmann A. Role of connexin32 and beta-catenin in tumor promotion in mouse liver. Toxicol Pathol 2003, 31:99-102.
163. Ogawa K., Yamada Y., Kishibe K., Ishizaki K., Tokusashi Y. Beta-catenin mutations are frequent in hepatocellular carcinomas but absent in adenomas induced by diethylnitrosamine in B6C3F1 mice. Cancer Res 1999, 59:1830-1833.
164. Devereux T.R., Anna C.H., Foley J.F., White C.M., Sills R.C., Barrett J.C. Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. Oncogene 1999, 18:4726-4733.
165. Calvisi D.F., Ladu S., Factor V.M., Thorgeirsson S.S. Activation of beta-catenin provides proliferative and invasive advantages in c-myc/TGF-alpha hepatocarcinogenesis promoted by phenobarbital. Carcinogenesis 2004, 25:901-908.
166. Calvisi D.F., Conner E.A., Ladu S., Lemmer E.R., Factor V.M., Thorgeirsson S.S. Activation of the canonical Wnt/beta-catenin pathway confers growth advantages in c-Myc/E2F1 transgenic mouse model of liver cancer. J Hepatol 2005, 42:842-849.
167. Calvisi D.F., Factor V.M., Loi R., Thorgeirsson S.S. Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res 2001, 61:2085-2091.
168. Zulehner G., Mikula M., Schneller D., van Zijl F., Huber H., Sieghart W., et al. Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. Am J Pathol 2010, 176:472-481.
169. Zhang X.F., Tan X., Zeng G., Misse A., Singh S., Kim Y., et al. Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology 2010, 52:954-965.
170. Rignall B., Braeuning A., Buchmann A., Schwarz M. Tumor formation in liver of conditional {beta}-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen. Carcinogenesis 2010.
171. Fujie H., Moriya K., Shintani Y., Tsutsumi T., Takayama T., Makuuchi M., et al. Frequent beta-catenin aberration in human hepatocellular carcinoma. Hepatol Res 2001, 20:39-51.
172. Huang H., Fujii H., Sankila A., Mahler-Araujo B.M., Matsuda M., Cathomas G., et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999, 155:1795-1801.
173. Kim Y.D., Park C.H., Kim H.S., Choi S.K., Rew J.S., Kim D.Y., et al. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma. J Gastroenterol Hepatol 2008, 23:110-118.
174. Kondo Y., Kanai Y., Sakamoto M., Genda T., Mizokami M., Ueda R., et al. Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma. Jpn J Cancer Res 1999, 90:1301-1309.
175. Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T., et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000, 24:245-250.
176. Taniguchi K., Roberts L.R., Aderca I.N., Dong X., Qian C., Murphy L.M., et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002, 21:4863-4871.
177. Merle P., de la Monte S., Kim M., Herrmann M., Tanaka S., Von Dem Bussche A., et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004, 127:1110-1122.
178. Nambotin S.B., Lefrancois L., Sainsily X., Berthillon P., Kim M., Wands J.R., et al. Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J Hepatol 2010.
179. Ban K.C., Singh H., Krishnan R., Seow H.F. GSK-3beta phosphorylation and alteration of beta-catenin in hepatocellular carcinoma. Cancer Lett 2003, 199:201-208.
180. Shih Y.L., Shyu R.Y., Hsieh C.B., Lai H.C., Liu K.Y., Chu T.Y., et al. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer 2006, 107:579-590.
181. Wong C.M., Fan S.T., Ng I.O. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001, 92:136-145.
182. Fukutomi T., Zhou Y., Kawai S., Eguchi H., Wands J.R., Li J. Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology 2005, 41:1096-1105.
183. Cha M.Y., Kim C.M., Park Y.M., Ryu W.S. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology 2004, 39:1683-1693.
184. Lian Z., Liu J., Li L., Li X., Clayton M., Wu M.C., et al. Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of beta-catenin. Hepatology 2006, 43:415-424.
185. Polakis P. Wnt signaling and cancer. Genes Dev 2000, 14:1837-1851.
186. Paul S., Dey A. Wnt signaling and cancer development: therapeutic implication. Neoplasma 2008, 55:165-176.
187. Monga S.P. Role of Wnt/beta-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol 2009.
188. Boyault S., Rickman D.S., de Reynies A., Balabaud C., Rebouissou S., Jeannot E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45:42-52.
189. Audard V., Grimber G., Elie C., Radenen B., Audebourg A., Letourneur F., et al. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J Pathol 2007, 212:345-352.
190. Nhieu J.T., Renard C.A., Wei Y., Cherqui D., Zafrani E.S., Buendia M.A. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999, 155:703-710.
191. Park J.Y., Park W.S., Nam S.W., Kim S.Y., Lee S.H., Yoo N.J., et al. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int 2005, 25:70-76.
192. Suzuki T., Yano H., Nakashima Y., Nakashima O., Kojiro M. Beta-catenin expression in hepatocellular carcinoma: a possible participation of beta-catenin in the dedifferentiation process. J Gastroenterol Hepatol 2002, 17:994-1000.
193. Mao T.L., Chu J.S., Jeng Y.M., Lai P.L., Hsu H.C. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol 2001, 193:95-101.
194. Yuan R.H., Jeng Y.M., Chen H.L., Hsieh F.J., Yang C.Y., Lee P.H., et al. Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis. Clin Cancer Res 2005, 11:2568-2575.
195. Yuan R.H., Jeng Y.M., Hu R.H., Lai P.L., Lee P.H., Cheng C.C., et al. Role of p53 and beta-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. J Gastrointest Surg 2010.
196. Dal Bello B., Rosa L., Campanini N., Tinelli C., Torello Viera F., D'Ambrosio G., et al. Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res 2010, 16:2157-2166.
197. Zucman-Rossi J., Jeannot E., Nhieu J.T., Scoazec J.Y., Guettier C., Rebouissou S., et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006, 43:515-524.
198. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
199. Yang J.D., Nakamura I., Roberts L.R. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2010.